Firms

415 Capital

415 Capital

Munich, Bavaria, Germany

415capital.com

415 Capital Management GmbH is a Munich medical-technology venture capital manager investing in clinical through commercial businesses in Europe, Israel and North America. Its focus includes cardiovascular and neurovascular disease, neuromodulation, medical robotics and imaging, and patient monitoring. Portfolio exposure includes ReEmerge’s brain-stimulation therapy and Laza Medical’s AI-assisted cardiovascular imaging and robotics. Its current public directories list ten investment-team staff, three senior advisers and thirteen external clinical advisers. The founders’ earlier CardioVentures investments and commercialized technologies form a predecessor track record. Fund I’s first close was announced in January 2020 with its amount undisclosed; Fund II’s October 2024 announcement describes a EUR150 million target, with no verified final-close amount.

Founded
—
Type
Venture capital

Funds2

  • 415 Capital Fund II GmbH & Co. KG—

    The October29,2024 manager announcement describes a EUR150million target and a majority of commitments secured, anticipating a Q1,2025 final close. No subsequent primary final amount verified; EUR150million target and its USD conversion are excluded from actual cash size.

  • 415 Capital Fund I GmbH & Co. KG—

    Primary January14,2020 announcement confirms an actual first close but does not disclose its size. The planned later final close of up to EUR85million is a target, not verified cash. Individual EIF commitments are not the whole-fund size.

Team

Operations and support

Amra HabichAmra HabichExecutive Assistant
Anna YildiranAnna YildiranInvestment Intern
Azin ParhizgarAzin ParhizgarManaging Director, US
David ThompsonDavid ThompsonGeneral Partner
Eduardo PalmaEduardo PalmaAssociate
Enrico FerroEnrico FerroSenior Clinical Advisor (external advisory affiliation)
Eric SecemskyEric SecemskySenior Clinical Advisor (external advisory affiliation)
Frank GroenewegenFrank GroenewegenChairman Emeritus (advisory affiliation)
Frederik GroenewegenFrederik GroenewegenGeneral Partner
Julia HoffmeisterJulia HoffmeisterSenior Investment Analyst
Linus RiederLinus RiederPrincipal
Marat FudimMarat FudimSenior Clinical Advisor (external advisory affiliation)
Marianne BrodmannMarianne BrodmannSenior Clinical Advisor (external advisory affiliation)
Matheus AbizaidMatheus AbizaidInvestment Analyst
Michael BraunMichael BraunSenior Venture Partner (advisory affiliation)
Michael LichtenbergMichael LichtenbergSenior Clinical Advisor (external advisory affiliation)
Moshe FlugelmanSenior Clinical Advisor (external advisory affiliation)
Nicolas Van MieghemNicolas Van MieghemSenior Clinical Advisor (external advisory affiliation)
Nicolo PiazzaNicolo PiazzaSenior Clinical Advisor (external advisory affiliation)
Peter SchneiderPeter SchneiderSenior Clinical Advisor (external advisory affiliation)
Rafael BeyarRafael BeyarSenior Clinical Advisor (external advisory affiliation)
Ruben OsnabruggeRuben OsnabruggePartner & Chief Medical Officer
Sam DawkinsSam DawkinsSenior Clinical Advisor (external advisory affiliation)
Steven BollingSteven BollingSenior Advisor (advisory affiliation)
Susheel KodaliSusheel KodaliSenior Clinical Advisor (external advisory affiliation)
Ulrich SchäferUlrich SchäferSenior Clinical Advisor (external advisory affiliation)

Co-investing

Investments